LYMPHOMA
Clinical trials for LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new LYMPHOMA trials appear
Sign up with your email to follow new studies for LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New vaccine strategy could shield lymphoma survivors from pneumonia
⭐️ VACCINE ⭐️ OngoingThis study looks at how well a pneumonia vaccine (PCV20) works in people who have recovered from B-cell lymphoma and were treated with anti-CD20 therapy. Researchers want to see if a single dose or a boosted dose is safer and more effective at preventing pneumococcal infections. …
Matched conditions: LYMPHOMA
Phase: PHASE4 • Sponsor: M.D. Anderson Cancer Center • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 11:00 UTC
-
New vaccine aims to better protect blood cancer patients from COVID-19
⭐️ VACCINE ⭐️ OngoingThis study tests a new COVID-19 vaccine (GEO-CM04S1) in 63 adults with blood cancers like leukemia or lymphoma who have had a stem cell transplant or cell therapy. The goal is to see if this vaccine triggers a stronger immune response than standard mRNA vaccines, potentially offe…
Matched conditions: LYMPHOMA
Phase: PHASE2 • Sponsor: GeoVax, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:04 UTC
-
New Three-Drug cocktail aims to tackle relapsed lymphoma
Disease control OngoingThis early-stage trial is testing a new drug called valemetostat together with two standard drugs (rituximab and lenalidomide) in 60 adults with follicular lymphoma that has come back or not responded to prior treatment. The main goal is to find a safe dose and check for side eff…
Matched conditions: LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug combo aims to tame blood cancer without chemo
Disease control OngoingThis phase 2 trial tests lenalidomide and rituximab in 120 people with chronic lymphocytic leukemia or small lymphocytic lymphoma. The goal is to see if this drug combination can control the disease, especially for those who cannot or choose not to have chemotherapy. Participants…
Matched conditions: LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug cocktail shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a combination of copanlisib (a targeted drug) with nivolumab (an immunotherapy) in people with advanced solid tumors or lymphoma. Some participants will also receive a third drug, ipilimumab. The main goals are to find the safest dose and to monitor s…
Matched conditions: LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take aim at returning blood cancers
Disease control OngoingThis early-phase trial tests the safety of giving patients modified immune cells from a donor to fight B-cell leukemia or lymphoma that has come back after a stem cell or organ transplant. The cells are designed to target a protein called CD19 on cancer cells. Only 19 patients ar…
Matched conditions: LYMPHOMA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
Engineered immune cells take aim at tough lymphomas in first human test
Disease control OngoingThis early-phase trial tests a new type of immunotherapy for people with Hodgkin lymphoma or cutaneous T-cell lymphoma that has returned or not responded to standard treatments. The therapy uses the patient's own T cells, which are genetically modified to recognize and attack can…
Matched conditions: LYMPHOMA
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Promising combo tackles rare blood cancer in chinese patients
Disease control OngoingThis study tests a combination of brentuximab vedotin plus standard chemotherapy (CHP) in 52 Chinese adults with a rare type of lymphoma called CD30+ peripheral T-cell lymphoma. The goal is to see how well the treatment shrinks tumors and to monitor side effects. Participants rec…
Matched conditions: LYMPHOMA
Phase: PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Supercharged immune cells aim to stop lymphoma comeback
Disease control OngoingThis early-phase trial tests a new treatment for people with Hodgkin or non-Hodgkin lymphoma who have had a stem cell transplant. The treatment uses the patient's own T cells, which are modified in a lab to recognize and attack cancer cells that carry a protein called CD30. The m…
Matched conditions: LYMPHOMA
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for older lymphoma patients: Four-Drug combo tested
Disease control OngoingThis phase 2 trial tests four different drug combinations in 373 patients aged 60 and older with untreated mantle cell lymphoma. The goal is to see which combination best delays cancer progression. Patients receive rituximab plus bendamustine, with or without bortezomib, followed…
Matched conditions: LYMPHOMA
Phase: PHASE2 • Sponsor: Eastern Cooperative Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New cocktail of 6 drugs takes on tough lymphomas
Disease control OngoingThis early-stage study tests a mix of six drugs (called ViPOR-P) in adults with B-cell lymphomas that came back or didn't respond to prior treatment. The goal is to see if the combination is safe and can shrink tumors. About 34 participants will take pills and receive infusions o…
Matched conditions: LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Donor stem cell transplant shows promise for tough blood cancers
Disease control OngoingThis study tests a stem cell transplant from a matched unrelated donor for people with advanced blood cancers or blood disorders. Patients get chemotherapy and radiation before the transplant to prepare their body, then take drugs to prevent the donor cells from attacking their o…
Matched conditions: LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Experimental combo aims to tame aggressive lymphoma without chemo
Disease control OngoingThis early-phase trial is testing a two-step approach for people with newly diagnosed, high-risk mantle cell lymphoma. First, patients receive a combination of acalabrutinib (a targeted drug) and rituximab (an antibody). Then, they get a one-time infusion of their own genetically…
Matched conditions: LYMPHOMA
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Heart-Smart cancer care: team approach tested in breast cancer patients
Disease control OngoingThis study tests whether extra care from a team of heart doctors, dietitians, exercise therapists, pharmacists, and physiotherapists can reduce side effects in breast cancer patients receiving chemotherapy. About 80 participants will be randomly assigned to either the team interv…
Matched conditions: LYMPHOMA
Phase: PHASE2 • Sponsor: University of Alberta • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New cocktail of drugs tested for Tough-to-Treat lymphoma
Disease control OngoingThis phase 2 trial is testing several new drug combinations for people with aggressive B-cell lymphoma that has come back or not responded to standard therapy. About 129 participants will receive one of several experimental combinations, including drugs like ibrutinib and selinex…
Matched conditions: LYMPHOMA
Phase: PHASE2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Double attack: radiation plus chemo shows promise for rare lymphoma
Disease control OngoingThis study tests whether giving radiation and chemotherapy at the same time can better control stage I or II nasal NK cell lymphoma. About 26 newly diagnosed adults are receiving this combination to see if it improves how long the disease stays away. The goal is to manage the can…
Matched conditions: LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Promising lymphoma combo trial pulled before it began
Disease control TerminatedThis study aimed to see if combining three drugs—epcoritamab, lenalidomide, and tafasitamab—could safely treat diffuse large B-cell lymphoma that had come back or stopped responding to treatment. It was designed for adults with certain types of B-cell lymphoma. However, the trial…
Matched conditions: LYMPHOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Lymphoma drug combo trial pulled before it started
Disease control TerminatedThis study was designed to test whether adding the drug tazemetostat to standard CHOP chemotherapy could improve outcomes for people with certain types of T-cell lymphoma. The trial was withdrawn before enrolling any participants, so no results are available. It would have includ…
Matched conditions: LYMPHOMA
Phase: PHASE2 • Sponsor: Eric Jacobsen, MD • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Experimental drug shows promise for Tough-to-Treat lymphoma
Disease control OngoingThis study tests a drug called CPI-613 in people with relapsed or hard-to-treat Burkitt lymphoma or high-grade B-cell lymphoma. About 24 participants aged 12 and older who have not responded to at least one prior treatment will receive the drug. The goal is to see if the drug can…
Matched conditions: LYMPHOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New cancer drug ASTX660 tested in patients with no other options
Disease control OngoingThis study tests a new drug called ASTX660 in people with advanced solid tumors or lymphomas that have not responded to standard treatments. The trial has two phases: first, to find the safest dose and check for side effects, and second, to see if the drug can shrink tumors or co…
Matched conditions: LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New hope for blood cancer patients: using mismatched donors for transplants
Disease control OngoingThis study tests a stem cell transplant using donors who are not a perfect match for patients with blood cancers like leukemia and lymphoma. Doctors give special drugs after the transplant to help prevent the donor cells from attacking the patient's body. The goal is to see if th…
Matched conditions: LYMPHOMA
Phase: PHASE2 • Sponsor: Center for International Blood and Marrow Transplant Research • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Could a custom chemo dose make stem cell transplants safer?
Disease control OngoingThis early-phase study tests a new way to calculate the dose of the chemotherapy drug melphalan for lymphoma patients about to receive a stem cell transplant. Instead of a fixed dose based on height and weight, researchers use a model that considers how previous patients processe…
Matched conditions: LYMPHOMA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New pill shows promise for Hard-to-Treat blood cancers
Disease control OngoingThis phase 2 trial tests an oral drug called sonrotoclax (BGB-11417) in 100 adults with chronic lymphocytic leukemia or small lymphocytic lymphoma that has come back or stopped responding to prior treatments. The goal is to see if the drug can shrink or control the cancer. It is …
Matched conditions: LYMPHOMA
Phase: PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug hope for rare blood disorder that causes anemia in cold weather
Disease control OngoingThis phase 2 trial tests the drug zanubrutinib (Brukinsa) in 25 people with primary cold agglutinin disease, a rare condition where the immune system attacks red blood cells in cold temperatures, causing anemia and poor circulation. The study aims to see if the drug can reduce an…
Matched conditions: LYMPHOMA
Phase: PHASE2 • Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New stem cell transplant approach shows promise for blood cancer patients without full matches
Disease control OngoingThis Phase 3 trial tested a stem cell transplant using blood stem cells from a half-matched (haploidentical) donor in 21 people with various blood cancers. The goal was to see if this approach could help patients who don't have a fully matched donor. Participants received chemoth…
Matched conditions: LYMPHOMA
Phase: PHASE3 • Sponsor: Dartmouth-Hitchcock Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New hope for aggressive lymphoma: targeted combo shows promise in early trial
Disease control OngoingThis study tests a new drug called glofitamab added to standard chemotherapy (R-CHOP) for people with a fast-growing type of lymphoma that has a high risk of coming back. The goal is to see if the combination is safe and helps more patients achieve complete remission. About 46 ad…
Matched conditions: LYMPHOMA
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Engineered immune cells take aim at hard-to-treat blood cancers in kids
Disease control OngoingThis study tests a new treatment for children and young adults up to age 30 whose leukemia or lymphoma has come back or not responded to standard therapy. The treatment uses the patient's own immune cells (T cells) that are genetically modified in a lab to recognize and attack ca…
Matched conditions: LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Immunotherapy drug tested for rare blood cancers
Disease control TerminatedThis study tests the drug pembrolizumab in people with certain aggressive lymphomas or rare histiocyte/dendritic cell cancers that have come back or not responded to treatment. The goal is to see if the drug can shrink tumors. The study is currently suspended and enrolled 18 part…
Matched conditions: LYMPHOMA
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Lower drug dose after transplant may cut infections without losing protection
Disease control OngoingThis study tests whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant from a partially matched donor, can reduce serious infections in the first 100 days while still preventing graft-versus-host disease (a common complication where donor cells att…
Matched conditions: LYMPHOMA
Phase: PHASE2 • Sponsor: Center for International Blood and Marrow Transplant Research • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Stem cell boost may extend remission in brain cancer trial
Disease control OngoingThis phase 2 trial tests whether adding a stem cell transplant to standard chemotherapy helps people with newly diagnosed primary CNS B-cell lymphoma live longer without their cancer returning. About 113 patients will receive either high-dose chemo plus a stem cell transplant or …
Matched conditions: LYMPHOMA
Phase: PHASE2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug shows promise for controlling rare skin cancers
Disease control OngoingThis study tests a drug called brentuximab vedotin in 79 people with rare skin lymphomas (ALCL, mycosis fungoides, or lymphomatoid papulosis) that have a marker called CD30. The goal is to see if the drug can shrink or control the cancer. Participants receive the drug every 3 wee…
Matched conditions: LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New antibody combo takes aim at Hard-to-Treat lymphoma
Disease control OngoingThis early-stage trial tests a new lab-made antibody called BYON4228, alone or with the cancer drug rituximab, in 17 people with relapsed or refractory B-cell non-Hodgkin lymphoma. The goal is to check safety and find the right dose. It's the first time this drug is being tested …
Matched conditions: LYMPHOMA
Phase: PHASE1 • Sponsor: Byondis B.V. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Can statins and steroids tame CAR-T's brain risks?
Disease control OngoingThis early-phase trial tests whether giving simvastatin (a cholesterol drug) and dexamethasone (a steroid) can safely prevent nerve-related side effects from axicabtagene ciloleucel (Axi-Cel) CAR-T therapy in adults with certain types of lymphoma. The study includes 37 participan…
Matched conditions: LYMPHOMA
Phase: EARLY_PHASE1 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Supercharged immune cells take on tough lymphomas
Disease control OngoingThis study tests a new treatment for people with Hodgkin or non-Hodgkin lymphoma that has returned or not responded to standard therapy. The treatment involves taking a patient's own T cells (a type of immune cell), adding a gene that helps them recognize and attack lymphoma cell…
Matched conditions: LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Double-Barreled CAR-T cells take aim at tough leukemia
Disease control OngoingThis early-phase study tests a new type of immunotherapy for children and young adults with leukemia that has come back or not responded to treatment. The therapy uses the patient's own immune cells, modified to recognize two different targets (CD19 and CD22) on leukemia cells, t…
Matched conditions: LYMPHOMA
Phase: PHASE1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Engineered immune cells with an emergency brake tested in lymphoma
Disease control OngoingThis early-phase study tests a new type of CAR T-cell therapy for people with B-cell lymphoma that has come back or not responded to treatment. The cells are engineered to target and kill cancer cells, but also include a safety switch that can be activated to reduce severe side e…
Matched conditions: LYMPHOMA
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New hope for kids with tough cancers: neratinib trial underway
Disease control OngoingThis study tests the safety and effectiveness of neratinib, a targeted cancer drug, in children whose solid tumors, brain tumors, lymphoma, or leukemia have come back or not responded to standard treatments. The drug is taken by mouth daily in 28-day cycles. The main goal is to f…
Matched conditions: LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New chemo cocktail aims to make stem cell transplants safer for seniors
Disease control OngoingThis early-phase study tests a combination of three drugs (rituximab, bendamustine, and melphalan) followed by a stem cell transplant using the patient's own cells. The goal is to see if this approach is safe and has fewer side effects than standard treatments for older adults wi…
Matched conditions: LYMPHOMA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Can a common antioxidant boost CAR T-Cell therapy for lymphoma?
Disease control OngoingThis early-phase trial tests whether adding N-Acetylcysteine (N-AC), an antioxidant, to standard CAR T-cell therapy (Yescarta) is safe for people with lymphoma. Nine participants receive different doses of N-AC to find the highest dose with few side effects. The goal is to see if…
Matched conditions: LYMPHOMA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New stem cell method aims to cut transplant risks for blood cancer patients
Disease control OngoingThis study tests a stem cell transplant method that removes certain immune cells (T and B cells) from donated stem cells before giving them to patients with blood cancers like leukemia or lymphoma. The goal is to help the new cells grow (engraft) while reducing the risk of graft-…
Matched conditions: LYMPHOMA
Phase: PHASE2 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Supercharged t cells take on Hard-to-Treat lymphoma
Disease control OngoingThis early-phase trial tests whether specially trained immune cells (T cells) that are made resistant to a tumor's defense chemical can safely fight relapsed EBV-positive lymphoma. Eight patients will receive two injections of these modified cells, 14 days apart, at increasing do…
Matched conditions: LYMPHOMA
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Supercharged immune cells take on Hard-to-Treat blood cancers
Disease control OngoingThis study tests a new type of immune therapy for people with certain blood cancers (CLL, lymphoma, or multiple myeloma) that have come back or not responded to treatment. Researchers take a patient's own T cells, add a special receptor that targets a protein called kappa on canc…
Matched conditions: LYMPHOMA
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Can digital nutrition help cancer patients fight malnutrition?
Disease control OngoingThis study tests whether improved nutritional support, delivered through digital tools and personalized advice, can reduce malnutrition in cancer patients. Around 130 adults with gynecologic, colorectal, or lymphoma cancers will receive either standard dietary advice or enhanced …
Matched conditions: LYMPHOMA
Phase: NA • Sponsor: University of Oslo • Aim: Disease control
Last updated Jun 26, 2026 14:40 UTC
-
New imaging agent could help spot hidden tumors
Diagnosis OngoingThis early study tests a new radioactive drug called [18F] Fluoroglutamine, which is designed to be used with PET scanners. Researchers want to see how long it stays in the blood and where it goes in the body, especially whether it collects in tumors. 67 adults with solid cancers…
Matched conditions: LYMPHOMA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 07:54 UTC
-
Can a simple test spot heart damage in cancer survivors?
Diagnosis OngoingThis study looks at whether a special ECG and a blood test can find early signs of heart weakness in adult cancer survivors who had certain chemotherapy. Researchers will check how well these tests work compared to standard heart imaging. The goal is to gather information needed …
Matched conditions: LYMPHOMA
Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Jun 26, 2026 13:34 UTC
-
Probiotic shows promise in preventing Life-Threatening transplant complication in kids
Prevention OngoingThis study tests whether a probiotic called Lactobacillus plantarum can prevent a serious complication called graft-versus-host disease (GvHD) in the gut of children receiving a donor stem cell transplant. About 173 children with blood cancers or other conditions are taking the p…
Matched conditions: LYMPHOMA
Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: Prevention
Last updated Jun 27, 2026 07:54 UTC
-
Talking therapy tackles tiredness in blood cancer patients
Symptom relief OngoingThis study looks at whether cognitive behavioral therapy (CBT) can help adults with acute myeloid leukemia or lymphoma who feel very tired from their cancer or treatment. Participants will attend up to 7 counseling sessions to learn skills to cope with fatigue, anxiety, and depre…
Matched conditions: LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
Remote exercise and education program aims to boost Well-Being in older cancer patients
Symptom relief OngoingThis study tests whether a 12-week program of online chair-based exercise and health education, combined with a geriatric assessment, is feasible and helpful for adults aged 65+ with certain cancers and their support persons. The program is delivered remotely, and the study will …
Matched conditions: LYMPHOMA
Phase: NA • Sponsor: Martine Puts • Aim: Symptom relief
Last updated Jun 27, 2026 12:24 UTC
-
Cancer patients may skip hospital stays with new home care program
Symptom relief OngoingThis study tests a program that lets cancer patients receive care at home while undergoing chemotherapy or radiation. It includes remote monitoring and home visits to reduce the need for hospital stays or emergency room visits. The goal is to see if this approach improves quality…
Matched conditions: LYMPHOMA
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Fasting during chemo: a new way to ease side effects?
Symptom relief ENROLLING_BY_INVITATIONThis study looks at whether fasting for 24 hours before and after chemotherapy is safe and doable for people with Hodgkin or Diffuse Large B Cell Lymphoma. 40 participants will either fast or follow standard care, tracking side effects, diet, and quality of life. The goal is to s…
Matched conditions: LYMPHOMA
Phase: NA • Sponsor: University of Oslo • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Mind over lymphoma: meditation trial aims to ease young Patients' distress
Symptom relief OngoingThis study tests whether a meditation-based mind-body program can improve quality of life for adolescents and young adults (ages 18-39) recently diagnosed with lymphoma. Participants practice guided meditation and mindfulness techniques to help lower distress, anxiety, and depres…
Matched conditions: LYMPHOMA
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 09:11 UTC
-
Can a phone app ease stress for childhood cancer survivors?
Symptom relief OngoingThis study looks at whether a daily mindfulness app called Headspace can help adults who survived childhood cancer cope with stress. Fifty survivors will use the app for 30 days and wear a wrist device to track stress signs. The main goal is to see if people find the app acceptab…
Matched conditions: LYMPHOMA
Phase: NA • Sponsor: St. Jude Children's Research Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 09:02 UTC
-
New program helps cancer patients and caregivers talk through tough emotions
Symptom relief OngoingThis study tests a communication program for people with advanced cancer and their caregivers. The goal is to help them manage difficult emotions and talk about the patient's illness and treatment wishes. About 45 participants will take part, and the program is tailored for Latin…
Matched conditions: LYMPHOMA
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC
-
Can a shorter radiation course tame relapsed lymphoma?
Symptom relief OngoingThis study tests whether a shorter course of radiation (over 2-3 weeks instead of the usual 5-6 weeks) is safe for people with Hodgkin or Non-Hodgkin lymphoma that has returned or not responded to treatment. About 30 participants will receive different radiation doses to find the…
Matched conditions: LYMPHOMA
Phase: NA • Sponsor: University of Chicago • Aim: Symptom relief
Last updated Jun 27, 2026 08:07 UTC
-
Cancer treatment gets personal: MATCH trial tests Gene-Guided drugs
Knowledge-focused OngoingThis phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …
Matched conditions: LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 01, 2026 23:00 UTC
-
Can a smart patch predict dangerous immune reactions in cancer treatment?
Knowledge-focused ENROLLING_BY_INVITATIONThis study tests whether a wearable patch called TempTraq can detect fevers earlier than standard temperature checks in cancer patients receiving immunotherapy. The goal is to see if continuous monitoring reduces the risk of severe cytokine release syndrome (CRS), a serious side …
Matched conditions: LYMPHOMA
Phase: NA • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Blood cell collection could open door to CAR T-Cell therapy for leukemia and lymphoma patients
Knowledge-focused ENROLLING_BY_INVITATIONThis study collects white blood cells from 120 people aged 3 to 65 with leukemia or lymphoma that hasn't been cured by standard treatments. The cells are gathered through a procedure called leukapheresis, then processed and frozen for future use in CAR T-cell therapy. The goal is…
Matched conditions: LYMPHOMA
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Frailty check could predict chemo danger for seniors
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at how frailty—a state of weakness and reduced physical function—affects the risk of severe side effects from chemotherapy in people aged 70 and older with cancer. Researchers will assess 160 patients using various tests for frailty, muscle loss, and overall heal…
Matched conditions: LYMPHOMA
Sponsor: Azienda Socio Sanitaria Territoriale Ovest Milanese, Ospedale di Legnano • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Massive farm study tracks Pesticide-Cancer links for decades
Knowledge-focused OngoingThis study follows nearly 90,000 farmers, their spouses, and pest control workers in Iowa and North Carolina over many years. Researchers track their exposure to pesticides and other farm chemicals, then monitor who develops cancer or other diseases. The goal is to identify which…
Matched conditions: LYMPHOMA
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Chemo brain under the microscope: largest study yet launched
Knowledge-focused OngoingThis study tracks over 1,400 breast cancer and lymphoma patients to see how chemotherapy affects memory, attention, and thinking skills. Researchers test patients before, right after, and up to years after treatment. The goal is to learn who is most at risk for 'chemo brain' and …
Matched conditions: LYMPHOMA
Sponsor: University of Rochester NCORP Research Base • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
New website aims to ease tough fertility choices for women with cancer
Knowledge-focused OngoingThis study tests a decision aid website called Pathways to Fertility for women newly diagnosed with cancer who may face infertility from treatment. About 130 women will use the website or receive standard care to see if it helps them make more informed and less conflicted decisio…
Matched conditions: LYMPHOMA
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
15-Year safety check for caribou cell therapy patients
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows about 150 people who previously received Caribou cell therapy for blood cancers like lymphoma or leukemia. Researchers will check for long-term side effects and overall survival for up to 15 years after treatment. No new treatment is given—this is just observat…
Matched conditions: LYMPHOMA
Sponsor: Caribou Biosciences, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
New full-body scanner may slash scan times for cancer patients
Knowledge-focused OngoingThis study compares a new total-body PET/CT scanner (uEXPLORER) with a conventional PET/CT scanner in 180 adults with lung cancer, lymphoma, or melanoma. Each participant gets scanned on both machines to see if the new scanner can produce equally good images in a shorter time. Th…
Matched conditions: LYMPHOMA
Phase: NA • Sponsor: University of California, Davis • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Can a 7-Day genomic test improve lymphoma treatment?
Knowledge-focused OngoingThis study looks at whether a new genomic test called the Molecular Functional (MF) Portrait can quickly provide useful information for treating lymphoma. Researchers will use tumor tissue already collected from 111 adults with diffuse large B-cell lymphoma to see if test results…
Matched conditions: LYMPHOMA
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
Botswana study reveals hidden link between HIV, EBV, and lymphoma
Knowledge-focused OngoingThis study examines stored lymph node samples from 100 people in Botswana who had lymphoma between 2012 and 2017. Researchers want to see how often Epstein-Barr virus (EBV) is found in these samples, and whether HIV infection makes a difference. The goal is to better understand t…
Matched conditions: LYMPHOMA
Sponsor: University of Pennsylvania • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
New imaging agent could help spot tumors in future cancer trials
Knowledge-focused OngoingThis early-phase study tests a radioactive imaging drug called 124I-PUH71 in 63 people with non-Hodgkin's lymphoma, myeloma, or solid tumors. The goal is to see how the drug travels through the body and collects in tumors, and how long it stays in the blood. This is not a treatme…
Matched conditions: LYMPHOMA
Phase: EARLY_PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Withdrawn study sought to understand when lymphoma and cancer strike together
Knowledge-focused TerminatedThis study was designed to look back at medical records of people in Picardy, France, who were diagnosed with both lymphoma and another cancer within six months between 2007 and 2012. The goal was to see if these cases were more common than expected and to describe patient charac…
Matched conditions: LYMPHOMA
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
CAR-T vaccine study pulled before it began
Knowledge-focused TerminatedThis study was designed to track how the immune system recovers after CAR-T cell therapy and to test a pneumococcal vaccine (PCV-21) in these patients. It planned to enroll 50 adults with blood cancers or solid tumors. However, the study was withdrawn before any participants were…
Matched conditions: LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Scientists seek tissue samples to unlock cancer mysteries
Knowledge-focused ENROLLING_BY_INVITATIONThis study collects blood and tissue samples from people receiving or donating bone marrow transplants for leukemia, lymphoma, or other blood diseases. Researchers will analyze these samples to find genes and proteins linked to cancer development and transplant complications. The…
Matched conditions: LYMPHOMA
Sponsor: Stanford University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
Mind over cancer? study explores power of positive thinking
Knowledge-focused TerminatedThis study aimed to see if changing how cancer patients think about their illness could improve their quality of life and treatment outcomes. Researchers planned to follow newly diagnosed patients and give some a short mindset training. However, the study was withdrawn before any…
Matched conditions: LYMPHOMA
Phase: NA • Sponsor: Stanford University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC